A phase 2 registrational trial of UCART19
Latest Information Update: 11 Nov 2019
At a glance
- Drugs UCART 19 (Primary)
- Indications Precursor cell lymphoblastic leukaemia-lymphoma
- Focus Registrational; Therapeutic Use
- Sponsors Servier
- 11 Nov 2019 New trial record
- 05 Nov 2019 According to an Allogene Therapeutics media release, the company will advance into potential Phase 2 registrational trials for UCART19 in 2020.